enGene Therapeutics Inc. balance sheet ENGNW

Annual Quarterly

As of Jul 31, 2026, enGene Therapeutics Inc. had total assets of $288.3 million and total liabilities of $58.0 million. Total assets were up 17.4% from a year earlier. Stockholders' equity was $230.3 million. It held $266.3 million in cash and investments against $7.9 million of total debt, net cash of $258.4 million. The current ratio, current assets divided by current liabilities, was 10.21.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Q3 FY2026
Jul 31, 2026
Q2 FY2026
Apr 30, 2026
Q1 FY2026
Jan 31, 2026
Q4 FY2025
Oct 31, 2025
Q3 FY2025
Jul 31, 2025
Q2 FY2025
Apr 30, 2025
Q1 FY2025
Jan 31, 2025
Q4 FY2024
Oct 31, 2024
Assets
Cash
41
+25.8%
30
-48.2%
37
-41.3%
50
-71.0%
33
-87.3%
58
-78.3%
62
-27.2%
173
+112.2%
Short-term investments
225
+33.1%
229
+43.0%
239
+58.0%
144
+119.8%
169
160
151
65
Long-term investments
0
-100.0%
27
-21.7%
37
-37.9%
9
-85.7%
23
34
59
60
Cash and investments
266
+18.4%
285
+13.4%
313
+14.6%
202
-32.1%
225
-12.7%
252
-5.0%
273
+218.5%
298
+265.4%
Total current assets
278
+31.5%
270
+18.4%
289
+30.1%
201
-18.6%
211
-19.6%
228
-15.4%
222
+148.2%
247
+189.5%
Property and equipment, net
2
+14.7%
2
+50.4%
2
+78.7%
2
+111.9%
2
+85.3%
2
+40.3%
1
+37.6%
1
+98.5%
Total assets
288
+17.4%
308
+15.3%
337
+17.9%
221
-28.8%
246
-8.0%
267
-2.5%
286
+206.1%
311
+257.8%
Liabilities and equity
Accounts payable
3
+6.6%
2
+14.4%
2
-6.5%
7
+374.0%
2
-16.7%
2
+642.7%
3
+104.3%
1
+22.1%
Total current liabilities
27
+33.1%
21
+19.4%
25
+90.0%
32
+118.1%
20
+51.9%
18
+185.8%
13
+87.6%
15
+178.9%
Total liabilities
58
+29.3%
52
+33.0%
56
+54.4%
54
+39.4%
45
+22.8%
39
+28.8%
36
+15.9%
39
+166.4%
Stockholders' equity
230
+14.8%
255
+12.3%
282
+12.6%
168
-38.5%
201
-12.9%
227
-6.5%
250
+300.7%
273
+276.1%
Debt
Lease liabilities
8
-4.1%
8
+366.8%
9
+388.8%
8
+370.5%
8
+334.2%
2
-9.6%
2
-12.4%
2
Total debt
8
-4.1%
8
+366.8%
9
+388.8%
8
+370.5%
8
+334.2%
2
-9.6%
2
-12.4%
2
Net cash
258
+19.3%
277
+10.9%
304
+12.2%
194
-34.5%
217
-15.3%
250
-5.0%
271
+224.0%
296
+263.2%
Ratios
Current ratio
10.21x
12.57x
11.75x
6.30x
10.34x
12.66x
17.16x
16.87x
Debt to equity
0.03x
0.03x
0.03x
0.05x
0.04x
0.01x
0.01x
0.01x
Return on equity
-56.61%
-49.71%
-43.49%
-69.94%
-47.20%
-35.14%
-27.62%
-20.23%
Return on assets
-45.21%
-41.25%
-36.32%
-52.97%
-38.58%
-29.96%
-24.15%
-17.72%
Book value per share
3.44
3.81
4.20
3.22
3.93
4.45
4.90
5.35
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ENGN (Nasdaq), ENGNW (Nasdaq)
Fiscal year ends
October 31
Incorporated in
Canada (Federal Level)
Headquarters
Saint-Laurent
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1980845
Former names
enGene Holdings Inc. (until Mar 9, 2026)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.